Sublicensees

Anhui Biochem Pharmaceutical

Sublicence covering: dolutegravir (DTG), tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG]

In June 2017,  ViiV Healthcare, the MPP and Anhui Biochem Pharmaceutical signed a sublicensing agreement to manufacture dolutegravir (DTG) for both paediatrics and adults use.

In June 2017, Gilead Sciences, the MPP and Anhui Biochem Pharmaceutical signed a sublicensing agreement allowing Anhui Biochem Pharmaceutical to manufacture tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), as well emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.

Aurobindo

Sublicences covering: daclatasvir (DCV), lopinavir/ritonavir (LPV/r), tenofovir alafenamide (TAF), atazanavir (ATV), abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

Aurobindo, Bristol-Myers Squibb and the MPP signed a sublicensing agreement in April 2016 allowing Aurobindo to develop daclatasvir (DCV).

In December 2015, following the announcement of MPP’s agreement with AbbVie, Aurobindo signed a sub-licensing agreement to produce lopinavir and ritonavir (LPV/r) for Africa.

In September 2014, Aurobindo, the MPP and Gilead Sciences signed a sublicensing agreement, which replaces the previous one signed in September 2011, allowing Aurobindo to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as  emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG]. The agreement was amended and restated in April 2016.

In July 2014, the MPP, Aurobindo and Bristol-Myers Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir (ABC) for paediatric use. This sublicensing agreement has been amended in November 2014 following the announcement of the extension of the MPP-ViiV Healthcare licence agreement to 121 countries.

top

Beximco Pharmaceuticals Ltd

Sublicence covering: daclatasvir (DCV)

In November, 2016, Bristol-Myers Squibb, the MPP and Beximco signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

top

Cipla

Sublicences covering: daclatasvir (DCV), atazanavir (ATV), tenefovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], dolutegravir (DTG)

In December 2015,  Bristol-Myers Squibb, the MPP and Cipla signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In November 2014, Cipla, the MPP and Bristol-Myers Squibb signed a sublicensing agreement related to the antiretroviral medicines atazanavir (ATV).

In September 2014, Cipla, the MPP and Gilead Sciences signed a new sublicensing agreement allowing Cipla to manufacture the novel investigational medicines tenofovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG]. The agreement was amended and restated in October 2015.

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

top

Desano

Sublicences covering: lopinavir/ritonavir(LPV/r), dolutegravir (DTG), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI) and atazanavir (ATV)

The MPP, Desano and AbbVie signed a sublicensing agreement, in June 2016, covering lopinavir/ritonavir (LPV/r) for Africa.

In November 2014, the MPP, Desano and ViiV Healthcare signed a sub-licensing agreement allowing Desano to manufacture dolutegravir (DTG) for adults and paediatrics use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

In August 2015, the MPP, Desano and Gilead Sciences signed a sub-licensing agreement, which replaces the previous one signed in September 2014, allowing Desano to manufacture tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), as well as elvitegravir (EVG) and the Quad.

In May 2014, the MPP  and Bristol-Myers Squibb signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano allowing it to manufacture atazanavir (ATV).

top

Dr Reddy’s Laboratories

Sublicence covering: dolutegravir (DTG), tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC)cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], lopinavir/ritonavir (LPV/r)

In June 2017,  ViiV Healthcare, the MPP and Dr Reddy’s Laboratories signed a sublicensing agreement to manufacture dolutegravir (DTG) for both paediatrics and adults use.

In July 2017, Dr Reddy’s Laboratories, the MPP and Gilead Sciences signed a sublicensing agreement allowing Dr Reddy’s Laboratories to manufacture tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad.

In July 2017, AbbVie, the MPP and Dr Reddy’s Laboratories signed a sublicensing agreement covering lopinavir/ritonavir (LPV/r) for Africa.

Emcure

Sublicences covering: lopinavir/ritonavir (LPV/r), daclatasvir (DCV), dolutegravir (DTG), tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

The MPP, Emcure and AbbVie signed a sublicensing agreement, in June 2016, covering lopinavir/ritonavir (LPV/r) for Africa.

In December 2015,  Bristol-Myers Squibb, the MPP and Emcure signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In October 2014, the MPP, Emcure and ViiV Healthcare signed a sublicensing agreement allowing Emcure to manufacture dolutegravir (DTG) for adults and paediatrics use. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

In September 2014, Emcure, the MPP and Gilead Sciences signed a new sublicensing agreement, which replaces the previous one signed in January 2012, allowing Emcure to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.  The agreement was amended and restated in March 2016.

In July 2014, the MPP and Bristol-Myers Squibb signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV).

top

Hetero Labs

Sublicences covering: atazanavir (ATV), raltegravir paediatrics (RAL), daclatasvir (DCV), lopinavir/ritonavir (LPV/r), tenofovir alafenamide (TAF), dolutegravir (DTG), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In July 2016, Hetero Labs signed an MPP sublicence to produce AbbVie’s lopinavir/ritonavir (LPV/r) for Africa.

In April 2016, MPP, Bristol-Myers Squibb and Hetero Labs signed a new sublicensing agreement allowing Hetero Labs to produce the HIV medicine atazanavir (ATV).

MPP, MSD and Hetero Labs signed a sublicensing agreement in December 2015, allowing Hetero to manufacture raltegravir (RAL) for paediatric use.

In December 2015, Bristol-Myers Squibb, the MPP and Hetero Labs signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In May 2015, the MPP, AbbVie and Hetero Labs signed a sublicensing agreement, allowing Hetero to manufacture paediatric formulations of  lopinavir and ritonavir (LPV/r) for paediatric use.

In September 2014, Hetero Labs, the MPP and Gilead Sciences signed a sublicensing agreement, replacing the previous one signed in July 2012, allowing Hetero Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad. The agreement was amended and restated in September 2015.

In August 2014, Hetero Labs, the MPP and ViiV Healthcare signed a sublicensing agreement allowing Hetero to manufacture a generic version of dolutegravir (DTG) for both paediatrics and adults use.

top

Huahai Pharmaceutical

Sublicences covering: tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), dolutegravir (DTG)

In May 2015, Huahai Pharmaceutical, the MPP and Gilead Sciences signed a sublicensing agreement allowing Huahai to manufacture and sell generic versions of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI). In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In June 2017, Huahai Pharmaceutical signed an MPP sublicence to produce ViiV Healthcare’s dolutegravir for adult use.

top

Laurus Labs

Sublicences covering: daclatasvir (DCV), tenofovir alafenamide (TAF), dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

MPP, Bristol-Myers Squibb and Laurus Labs entered into a sublicensing agreement in April 2016 allowing Laurus to produce daclatasvir (DCV). 

In September 2014, Laurus Labs, the MPP and Gilead Sciences signed a new sublicensing agreement, replacing the previous one signed in September 2012, allowing Laurus Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well as tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad. In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatric and adult use.

top

Lupin

Sublicences covering: raltegravir (RAL) paediatrics, tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), Quad, dolutegravir (DTG), lopinavir, ritonavir (LPV/r)

The MPP, MSD and Lupin signed a sublicensing agreement in April 2016 allowing Luping to develop and manufacture raltegravir (RAL) for paediatric use. 

In June 2015, the MPP, Lupin and Gilead Sciences signed a sub-licensing agreement allowing Lupin to produce a generic version of tenofovir alafenamide (TAF) as well as of emtricitabine (FTC), cobicistat (COBI) and the Quad.  In September 2015, Gilead and the MPP clarified section 2.5b(ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In June 2015, the MPP announced a sublicensing agreement with Lupin allowing it to manufacture dolutegravir (DTG) for both paediatrics and adults use.

In April 2017, Lupin signed a MPP sublicence to produce AbbVie’s lopinavir, ritonavir (LPV/r).

 

Macleods

Sublicence covering: dolutegravir (DTG), tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG]

In June 2017,  ViiV Healthcare, the MPP and Macleods signed a sublicensing agreement to manufacture dolutegravir (DTG) for both paediatric and adult use.

In June 2017, Macleods, the MPP and Gilead Sciences signed a sublicensing agreement allowing Macleods to manufacture tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad.

top

Micro Labs

Sublicence covering: tenofovir alafenamide (TAF), emtricitabine (FTC), Quad, dolutegravir (DTG)

In September 2015, the MPP, Micro Labs and Gilead Sciences signed a sublicensing agreement allowing Micro Labs to produce a generic version of tenofovir alafenamide (TAF) as well as of emtricitabine (FTC) and the Quad. In September 2015, Gilead and the MPP clarified section 2.5b (ii) of the agreement confirming that as soon as the TAF Quad is approved by the US FDA, any combination containing TAF can be manufactured and commercialised by MPP’s licensees.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Micro Labs allowing it to manufacture dolutegravir (DTG) for both adult and paediatric treatment. The adult licence was amended in April 2016 to extend the licensing territory to all lower middle-income countries.

top

Mylan

Sublicences covering: daclatasvir (DCV), dolutegravir (DTG) and atazanavir (ATV)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Mylan allowing it to manufacture dolutegravir (DTG) for both adult and paediatric use.

In July, 2016, the MPP and Bristol-Myers Squibb signed a sublicensing agreement with Mylan allowing it to manufacture atazanavir (ATV).

In October 2016, Bristol-Myers Squibb, the MPP and Mylan signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

top

Natco Pharma Limited

Sublicence covering: daclatasvir (DCV), tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG]

In December 2015,  Bristol-Myers Squibb, the MPP and Natco signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

In June 2017, Natco, the MPP and Gilead Sciences signed a sublicensing agreement allowing Natco to manufacture tenofovir alafenamide (TAF),tenofovir disoproxil fumarate (TDF)emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.

top

Sandoz

Sublicence covering: daclatasvir (DCV)

In November 2016, Bristol-Myers Squibb, the MPP and Sandoz signed a sublicensing agreement with the aim of increasing access to the hepatitis C medicine daclatasvir (DCV). 

top

Strides Shasun

Sublicences covering: dolutegravir (DTG) paediatrics and adults. 

In June 2015, the MPP announced a sublicensing agreement with Strides Shasun allowing it to manufacture dolutegravir (DTG) for both paediatric and adult use.

top

Sun Pharma

Sublicence covering:  lopinavir, ritonavir (LPV/r), dolutegravir (DTG)

In March 2017, Sun signed an MPP sublicence to produce AbbVie’s lopinavir, ritonavir (LPV/r)

In June 2017, ViiV Healthcare, the MPP and Sun signed a sublicensing agreement to manufacture dolutegravir (DTG) for both paediatric and adult use.

top

TB Alliance

Sublicence covering:  sutezolid

In March 2017, the MPP and TB Alliance signed a sublicensing agreement for the clinical development of tuberculosis drug candidate sutezolid. The agreement follows the MPP’s licence for the treatment signed with patent holder The Johns Hopkins University in January 2017.

top

Zydus Cadila

Sublicence covering:  daclatasvir (DCV)

In April 2016, the MPP, Bristol-Myers Squibb and Zydus Cadila signed a sublicensing agreement allowing it to manufacture daclatasvir (DCV). 

top

This page is also available in: French, Spanish